Vitality Watch

Dossier clinicaltrials trial early 13-nov-2026
Small or early-phase human trial or pilot study

Sativex® and Gentamicin for Optimized Pharmagological Treatment in Older Patients (CanPan)

Key claim: The CanPan trial evaluates whether Sativex can stimulate appetite and how altered body composition and organ function in malnourished older patients affect the pharmacokinetics of lipophilic and hydrophilic drugs.

Abstract

Malnutrition and inappropriate prescribing of renally excreted drugs are common among older persons and are associated with severe consequences such as complicated courses of treatment, mortality, and reduced quality of life. The overall purpose of CanPan is to optimize treatment of older persons with malnutrition with a focus on appetite stimulation and optimized prescribing of renal risk drugs.

The CanPan trial consists of two sub-studies. Substudy 1 will provide knowledge on appetite and appetite stimulation and together, sub study 1 and 2 will offer unique knowledge on how body composition, renal function and biomarkers of organ function influence pharmacokinetics for a highly lipophilic (Sativex®) and hydrophilic (Hexamycin®) drug in older medical patients with malnutrition.

Why this matters

The CanPan trial evaluates whether Sativex can stimulate appetite and how altered body composition and organ function in malnourished older patients affect the pharmacokinetics of lipophilic and hydrophilic drugs.

Source

Link

Briefing card

Sativex® and Gentamicin for Optimized Pharmagological Treatment in Older Patients (CanPan)
Stage: trial early · clinicaltrials · 13-nov-2026

The CanPan trial evaluates whether Sativex can stimulate appetite and how altered body composition and organ function in malnourished older patients affect the pharmacokinetics of lipophilic and hydrophilic drugs.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT05503147

build build 880 · 2bcef25 · 2026-11-18